FIND Tuberculosis Strain Bank: a Resource for Researchers and Developers Working on Tests To Detect Mycobacterium tuberculosis and Related Drug Resistance

Tessema, Belay; Nabeta, Pamela; Valli, Eloise; Albertini, Audrey; Collantes, Jimena; Lân, Nguyễn Hữu; Romancenco, Elena; Tukavdze, Nestani; Denkinger, Claudia M.; Dolinger, David L.

doi:10.1128/jcm.01662-16

Cited by 21 publications

(13 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…So far, there have been many well studied, conserved target regions for MTB, which include rpo B, kat G, inh A, IS6110, IS1081, etc. [16,17]. These genetic regions have also been commonly used for the development of clinical in vitro diagnostic products for MTB.…”

Section: Methodsmentioning

confidence: 99%

CRISPR-based rapid and ultra-sensitive diagnostic test for Mycobacterium tuberculosis

Zhou

Teng

et al. 2019

Emerging Microbes & Infections

159

123

View full text Add to dashboard Cite

Rapid and simple-to-use diagnostic methods for tuberculosis are urgently needed. Recent development has unveiled the diagnostic power of the CRISPR system in the detection of viral infections. However, its potential use in detecting the Mycobacterium tuberculosis complex (MTB) remained unexplored. We developed a rapid CRISPR-based assay for TB detection and conducted a retrospective cohort study of 179 patients to evaluate the CRISPR-MTB test for identifying MTB in various forms of direct clinical samples. Its diagnostic performance was compared, in parallel with culture and the GeneXpert MTB/RIF assay (Xpert). The CRISPR-MTB test is highly sensitive with a near single-copy sensitivity, demands less sample input and offers shorter turnaround time than Xpert. When evaluated in the clinical cohort of both pulmonary and extra-pulmonary tuberculosis, the CRISPR-MTB test exhibited an overall improved sensitivity over both culture (79% vs 33%) and Xpert (79% vs 66%), without comprise in specificity (62/63, 98%). The CRISPR-MTB test exhibits an improved overall diagnostic performance over culture and Xpert across a variety of sample types, and offers great potential as a new diagnostic technique for both pulmonary and extra-pulmonary tuberculosis.

show abstract

Section: Methodsmentioning

confidence: 99%

CRISPR-based rapid and ultra-sensitive diagnostic test for Mycobacterium tuberculosis

Zhou

Teng

et al. 2019

Emerging Microbes & Infections

159

123

View full text Add to dashboard Cite

show abstract

“…Tuberculosis (TB), caused by Mycobacterium tuberculosis, remains the most deadly infectious diseases and one of the top 10 causes of the death worldwide in 2015. Report provided by WHO showed that there are 10.4 million new cases and 1.44 million deaths in 2015, where 480,000 new cases are associated with multidrug-resistant TB (MDR-TB) with an additional 100,000 people with rifampicin-resistant TB (RR-TB) (Tessema et al 2017). The notorious tendency of M. tuberculosis with the conjunction of prolonged treatment regimens shows drug resistant which is developed in different stages (Connolly et al 2007).…”

Section: Introductionmentioning

confidence: 99%

Molecular docking and dynamics of Nickel-Schiff base complexes for inhibiting β-lactamase of Mycobacterium tuberculosis

Junaid¹,

Alam²,

Hossain³

et al. 2018

In Silico Pharmacol.

View full text Add to dashboard Cite

In recent years, multidrug-resistance has become a primary concern in the treatment and management of tuberculosis, an infectious disease caused by Mycobacterium tuberculosis. In this context, searching new anti-tuberculosis agents particularly targeting the β-lactamase (BlaC) is reported to be promising as this enzyme is one of the key player in the development of multidrug resistance. This study reports the design of some Nickel (Ni) based tetradentate N 2 O 2 Schiff bases, employing density functional theory. All analogs are optimized at B3LYP/SDD level of theory. Dipole moment, electronic energy, enthalpy, Gibbs free energy, HOMO-LUMO gap, and softness of these modified drugs are also investigated. Molecular interactions between designed ligands and BlaC have been analyzed by molecular docking approach, followed by molecular dynamics (MD) simulation. All designed compounds show low HOMO-LUMO gap, while addition of halogen increases the dipole moment of the compounds. Docking and MD simulation investigations reveal that the designed compounds are more potent than standard inhibitor, where Ile117, Pro290, Arg236 and Thr253 residues of BlaC are found to play important role in the ligand binding. Through MD simulation study, the best binding compound is also observed to form stable complex by increasing the protein rigidness. The ADME/T analysis suggests that modified drugs are less toxic and shows an improved pharmacokinetic properties than that of the standard drug. These results further confirm the ability of Ni-directed Schiff bases to bind simultaneously to the active site of BlaC and support them as potential candidates for the future treatment of tuberculosis disease.

show abstract

“…This intermediate range corresponds to specific mutations (e.g. gyrA A90V and D94A), whereas other mutations, such as gyrA D94G, confer higher MICs and consequently fall into the category of HLR . Such stratified pDST is already in use for INH where inhA c‐15t promotor mutations corresponding to intermediate MICs at 0.2–1 mg L −1 have been associated to favourable clinical outcomes and an increased dosing is suggested (15–20 mg kg −1 ) whereas katG S315T mutations are associated to higher MICs (>2 mg L −1 ) which cannot be overcome by increased dosing .…”

Section: Stratified Phenotypic Drug Susceptibilitymentioning

confidence: 99%

Perspectives for personalized therapy for patients with multidrug‐resistant tuberculosis

et al. 2018

View full text Add to dashboard Cite

According to the World Health Organization (WHO), tuberculosis is the leading cause of death attributed to a single microbial pathogen worldwide. In addition to the large number of patients affected by tuberculosis, the emergence of Mycobacterium tuberculosis drug-resistance is complicating tuberculosis control in many high-burden countries. During the past 5 years, the global number of patients identified with multidrug-resistant tuberculosis (MDR-TB), defined as bacillary resistance at least against rifampicin and isoniazid, the two most active drugs in a treatment regimen, has increased by more than 20% annually. Today we experience a historical peak in the number of patients affected by MDR-TB. The management of MDR-TB is characterized by delayed diagnosis, uncertainty of the extent of bacillary drug-resistance, imprecise standardized drug regimens and dosages, very long duration of therapy and high frequency of adverse events which all translate into a poor prognosis for many of the affected patients. Major scientific and technological advances in recent years provide new perspectives through treatment regimens tailor-made to individual needs. Where available, such personalized treatment has major implications on the treatment outcomes of patients with MDR-TB. The challenge now is to bring these adances to those patients that need them most.

show abstract

FIND Tuberculosis Strain Bank: a Resource for Researchers and Developers Working on Tests To Detect Mycobacterium tuberculosis and Related Drug Resistance

Cited by 21 publications

References 13 publications

CRISPR-based rapid and ultra-sensitive diagnostic test for Mycobacterium tuberculosis

CRISPR-based rapid and ultra-sensitive diagnostic test for Mycobacterium tuberculosis

Molecular docking and dynamics of Nickel-Schiff base complexes for inhibiting β-lactamase of Mycobacterium tuberculosis

Perspectives for personalized therapy for patients with multidrug‐resistant tuberculosis

Contact Info

Product

Resources

About